These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Warfarin Dosing According to the Genotype-guided Algorithm is Most Beneficial in Patients With Atrial Fibrillation: A Randomized Parallel Group Trial. Makar-Aušperger K; Krželj K; Lovrić Benčić M; Radačić Aumiler M; Erdeljić Turk V; Božina N Ther Drug Monit; 2018 Jun; 40(3):362-368. PubMed ID: 29494423 [TBL] [Abstract][Full Text] [Related]
10. Validation of a proposed warfarin dosing algorithm based on the genetic make-up of Egyptian patients. Ekladious SM; Issac MS; El-Atty Sharaf SA; Abou-Youssef HS Mol Diagn Ther; 2013 Dec; 17(6):381-90. PubMed ID: 23839801 [TBL] [Abstract][Full Text] [Related]
11. Validation of pharmacogenetic algorithms and warfarin dosing table in Egyptian patients. Bazan NS; Sabry NA; Rizk A; Mokhtar S; Badary O Int J Clin Pharm; 2012 Dec; 34(6):837-44. PubMed ID: 22851439 [TBL] [Abstract][Full Text] [Related]
12. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Sconce EA; Khan TI; Wynne HA; Avery P; Monkhouse L; King BP; Wood P; Kesteven P; Daly AK; Kamali F Blood; 2005 Oct; 106(7):2329-33. PubMed ID: 15947090 [TBL] [Abstract][Full Text] [Related]
13. Preliminary outcomes of preemptive warfarin pharmacogenetic testing at a large rural healthcare center. Leary E; Brilliant M; Peissig P; Griesbach S Am J Health Syst Pharm; 2019 Feb; 76(6):387-397. PubMed ID: 31415684 [TBL] [Abstract][Full Text] [Related]
14. Changing from mandatory to optional genotyping results in higher acceptance of pharmacist-guided warfarin dosing. Zolekar A; Kim K; Lee JC; Han J; Duarte JD; Galanter WL; Cavallari LH; Nutescu EA Pharmacogenomics; 2022 Jan; 23(2):85-95. PubMed ID: 35001645 [No Abstract] [Full Text] [Related]
15. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients. Miao L; Yang J; Huang C; Shen Z Eur J Clin Pharmacol; 2007 Dec; 63(12):1135-41. PubMed ID: 17899045 [TBL] [Abstract][Full Text] [Related]
16. The potential clinical and economic outcomes of pharmacogenetics-oriented management of warfarin therapy - a decision analysis. You JH; Chan FW; Wong RS; Cheng G Thromb Haemost; 2004 Sep; 92(3):590-7. PubMed ID: 15351856 [TBL] [Abstract][Full Text] [Related]
17. Extremely low warfarin dose in patients with genotypes of CYP2C9*3/*3 and VKORC1-1639A/A. Gao L; He L; Luo J; Xu B; Yang J; Zhang YX; Yang T; Li K; Tian JW; Wang HJ; Zhao YS; Lu CY; Zhang WZ; Yin T Chin Med J (Engl); 2011 Sep; 124(17):2767-70. PubMed ID: 22040439 [TBL] [Abstract][Full Text] [Related]
18. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Johnson JA; Gong L; Whirl-Carrillo M; Gage BF; Scott SA; Stein CM; Anderson JL; Kimmel SE; Lee MT; Pirmohamed M; Wadelius M; Klein TE; Altman RB; Clin Pharmacol Ther; 2011 Oct; 90(4):625-9. PubMed ID: 21900891 [TBL] [Abstract][Full Text] [Related]
19. Warfarin pharmacogenetics: development of a dosing algorithm for Omani patients. Pathare A; Al Khabori M; Alkindi S; Al Zadjali S; Misquith R; Khan H; Lapoumeroulie C; Paldi A; Krishnamoorthy R J Hum Genet; 2012 Oct; 57(10):665-9. PubMed ID: 22854539 [TBL] [Abstract][Full Text] [Related]
20. Pharmacogenomics of warfarin: uncovering a piece of the warfarin mystery. Gulseth MP; Grice GR; Dager WE Am J Health Syst Pharm; 2009 Jan; 66(2):123-33. PubMed ID: 19139476 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]